Seeking Alpha

Venaxis, Inc. (APPY)

  • LaboMedic | Send Message 29 Jan

    $APPY UPDATE: Canaccord Downgrades Venaxis After Significant FDA Setback
      • pat45 | Send Message 29 Jan

        Bot $APPY .56 it has .80 cash but .43 burn and don't know how long till test approved in USA . Has CE Mark
        Reply (1)
        • pat45 | Send Message 29 Jan
          : I have been in and out of this one will hold a while now. Hope can prove equivalent soon.
          • LaboMedic | Send Message 14 Dec 2014

            Analyst Highlights - Week 50 - Healthcare (Part IV) $APPY $AGIO $MRK $CELG $DVAX
              • LaboMedic | Send Message 10 Dec 2014

                $APPY Canaccord Genuity Maintains Buy On Venaxis, Sees 184% Upside
                  • stem23 | Send Message 9 Dec 2014

                    $APPY - If FDA has no further inquiries, expect FDA announce no later then March. Company is confident of response to FDA questions
                      • pat45 | Send Message 4 Dec 2014

                        Bot back $APPY sales soon in Europe where it is approved and meeting with FDA soon.
                          • Blair O'Neill | Send Message 29 Oct 2014

                            Venaxis: Latest Clinical Data Reveals Huge Market Potential $APPY
                              • stem23 | Send Message 27 Oct 2014

                                $APPY STOCK MOVES on
                                  • wrc123 | Send Message 9 Oct 2014

                                    $APPY FDA file should be around November...according to CEO interview by
                                      • shofimafi | Send Message 8 Oct 2014

                                        $APPY Looks like the FDA refile is any day now
                                          Visit Seeking Alpha's
                                          APPY vs. ETF Alternatives
                                          Company Description
                                          Venaxis Inc is engaged in the development and commercialization of innovative products that address unmet diagnostic and therapeutic needs.